Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling

Academic Article

Abstract

  • The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup has organized an annual workshop focused on minimal residual disease (MRD) testing and immune profiling (IP) in multiple myeloma since 2016. In 2019, the workshop took place as an American Society of Hematology (ASH) Friday Scientific Workshop titled “Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma.” This workshop focused on 4 main topics: the molecular and immunologic evolution of plasma cell disorders, development of new laboratory- and imaging-based MRD assessment approaches, chimeric antigen receptor T cell therapy research, and statistical and regulatory issues associated with novel clinical endpoints. In this report, we provide a summary of the workshop and discuss future directions.
  • Digital Object Identifier (doi)

    Author List

  • Holstein SA; Howard A; Avigan D; Bhutani M; Cohen AD; Costa LJ; Dhodapkar MV; Gay F; Gormley N; Green DJ
  • Start Page

  • e247
  • End Page

  • e255
  • Volume

  • 26
  • Issue

  • 10